Search Results for "Sjogren A Belimumab"

13:47 EDT 5th July 2015 | BioPortfolio

Matching Channels

None

Matching News

Molecule identified that could lead to new drugs for lupus and Sjogren’s

An inflammatory molecule that appears to play an essential role in systemic lupus erythematosus has been identified by a team from Massachusetts General Hospital, they report in Nature Immunology. The...

Role of Novel Hepatitis Delta Virus Variant in Sjogren’s Syndrome

A diagnosis of rheumatoid arthritis and Sjogren’s when she was 22 years old sent Cristina Montoya into a deep depression. But medication, meditation and dietary changes helped her retake control

In 2004 I was training to be a dietitian in Colombia, where I’m originally from. I was working at a hospital in Medellin, and the elevator was not working so we had to go up and down the stairs many...

Aldeyra Therapeutics Announces First Patient Enrolled in Sjogren-Larsson Syndrome Phase II Clinical Trial

LEXINGTON, Mass., March 24, 2015 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to fr...

A diagnosis of rheumatoid arthritis and Sjogren’s when she was 22 years old sent Cristina Montoya into a deep depression. But medication, meditation and dietary control helped her retake control

In 2004 I was training to be a dietitian in Colombia, where I’m originally from. I was working at a hospital in Medellin, and the elevator was not working so we had to go up and down the stairs many...

Arthritis Is Major Risk With Antibody-Positive Sjogren?s

(MedPage Today) -- And almost a third of patients developing RA had the erosive form

Aldeyra Therapeutics to Present Novel Data on a Potential Treatment for Sjogren-Larsson Syndrome at the 2015 Society for Inherited Metabolic Disorders Annual Meeting

LEXINGTON, Mass., Jan. 29, 2015 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to fre...

B-Cell Antibody Modestly Improves Sjogren?s Symptoms (CME/CE)

(MedPage Today) -- Study says further randomized, controlled trials needed to gauge effectiveness.

Matching PubMed Articles

Update on belimumab for the management of systemic lupus erythematosus.

Introduction: Belimumab is a fully humanised mAb against B lymphocyte stimulator (B-LyS). It is the first biological drug to be licensed and approved by the US FDA and the European Medicines Evaluatio...

Cost-effectiveness analysis of Belimumab in patients with systemic lupus erythematosus in Spain.

To estimate the cost-effectiveness of belimumab in patients with systemic lupus erythematosus (SLE) presenting positive biomarkers and active disease despite standard treatment (ST), from the Spanish ...

Belimumab and the measurement of fatigue.

New treatments for inflammatory rheumatic disease.

As our understanding of the pathogenesis of autoimmune diseases is growing, new therapies are being developed to target disease-specific pathways. Since the introduction of etanercept in 1998, several...

IL-22 receptor 1 is over-expressed in primary Sjogren's Syndrome and Sjogren-associated non-Hodgkin lymphomas and is regulated by IL-18.

Aim of this study was to better elucidate the role of interleukin (IL)-18 in modulating the IL-22 pathway in primary Sjogren's syndrome (pSS) patients and in pSS-associated lymphomas.

Search Whole site using Google

Loading

Advertisement
 
Advertisement
 
Advertisement Advertisement